MedTrace Logo

Iloprost in High Risk Cardiac Surgical Patients

NCT00927654 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2013-01-07

No results posted yet for this study

Summary

In this study effects of the intra operative, prophylactic inhalation of Iloprost (Ventavis) before and during extracorporal circulation on perioperative morbidity and outcome in high risk cardiac surgical patients is investigated in comparison to placebo.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Iloprost (Ventavis)

Twice 20 µg at day 0 (total dose 40 µg) intraoperatively

DRUG

Isotonic Sodium Chloride solution 0.9 % (placebo)

Twice at day 0 intraoperatively

Sponsors & Collaborators

  • Algora

    collaborator UNKNOWN

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Bernhard Zwissler, Prof.Dr.med. · Ludwig-Maximilians - University of Munich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00927654 on ClinicalTrials.gov